Alacris Theranostics GmbH, based in Berlin, is a small corporation within the meaning of § 267 (1) HGB and is registered at the Charlottenburg commercial register under HRB 114897 B. The annual financial statements were prepared in accordance with the provisions of Book Three of the HGB and the profit and loss account was prepared using the total cost method. In the 2024 financial year, an average of 10 employees including management were employed, and management was held by Dr. Bodo Lange. The company had a supervisory advisory board of four persons, including Prof. Dr. Hans Lehrach as chairman, and the financial statements were adopted on 30 June 2025. The company is a small company under § 267 (1) HGB and is therefore not required to publish a profit-and-loss statement.
Das Ziel, systembiologische Ansätze, die in den Arbeitsgruppen der Gründer entwickelt wurden, in der Entwicklung neuer Medikamente sowie auf Basis einer detaillierten molekularen Analyse von Patientenmaterial, zur Voraussage der Wirkungen und Nebenwirkungen (ohne direkte Verabreichung) von Medikamenten auf individuelle Patienten einzusetzen.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 114897 (as of 20 November 2026)
| Name | Type | City |
|---|---|---|
| Bodo Lange | Geschäftsführer(in) | Berlin |
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 114897 (as of 20 November 2026)
| Date | Event Type | Event |
|---|---|---|
| 30.06.2017 | Business Address Change | Max-Planck-Straße 3, 12489 Berlin |
| 16.01.2012 | Gesellschaftsvertrag amended | Gesellschaftsvertrag |
| 16.12.2011 | Business Address Change | Fabeckstr. 60-62, 14195 Berlin |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 12.08.2008 | Share Capital Set | — | 25.000 € |
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 114897 (as of 20 November 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2025 | Gross profit€1.2M2 | -€367,583 | €5,017,202 | 10 |
| 2024 | Gross profit€1.3M2 | -€226,286 | €4,151,855 | 10 |
| 2023 | Gross profit€1.3M2 | -€115,650 | €3,570,875 | 12 |
| 2022 | Gross profit€1.4M2 | -€21,182 | €2,831,801 | 13 |
| 2021 | Gross profit€1.6M2 | -€169,421 | €2,773,055 | 20 |
| 2020 | Gross profit€1.4M2 | -€719,399 | €2,955,428 | 23 |
| 2019 | Gross profit€1.6M2 | -€439,416 | €2,996,243 | 24 |
| 2018 | small company1 | -€108,719 | €2,882,739 | 21 |
| 2017 | small company1 | €19,155 | €2,497,518 | 23 |
| 2016 | small company1 | -€181,763 | €2,211,423 | 21 |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Gross profit under § 276 HGB: revenue less the cost of materials or cost of sales. Small and medium-sized companies may combine these items; revenue itself is then not disclosed and exceeds gross profit.
Source: German Company Register (Unternehmensregister) · Annual accounts
Sign in to download data
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 114897 (as of 20 November 2026)
Forschungs-GmbH Wismar
Wismar · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin
Arcensus GmbH
Rostock · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin
ef.Ruhr GmbH
Dortmund · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin